Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

ChinaBio® Partnering Forum: Top 5 Risks and Opportunities to Watch in China Life Sciences in 2023

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

According to Deloitte’s 2022 Global Life Sciences Report, 2023 will be challenging and transformative for life sciences companies.

According to Deloitte’s 2022 Global Life Sciences Report, 2023 will be challenging and transformative for life sciences companies.<ul><li dir="ltr">Swift shifts to more data-driven approaches across the value chain of the industry brings data security in multijurisdictional operations to the top of investors’ minds.</li><li dir="ltr">Out of growing geopolitical concerns, how to manage IPs so that they can be in neutral jurisdictions and how to carefully manage data export has been heatedly discussed and will continue to be a key topic.</li><li dir="ltr">Furthermore, AI is reshaping the industry in all areas from drug discovery and clinical trials to patient experience and pharmacovigilance. How companies could effectively make use of AI is a key to success in the year to come.</li><li dir="ltr">The past three years of the pandemic has brought huge financial stress to life sciences companies; therefore, innovative ways to monetize assets will position the investors to a more advantageous role. </li><li dir="ltr">As companies are moving towards commercialization of their products, identifying and mitigating potential risks of patent infringement lawsuits is central to their business strategy.</li></ul>In this session, we bring a panel of legal leaders to discuss the above topics to help life sciences companies navigate through the turmoil. The panel will be moderated by Morrison Foerster Partner Janet Xiao, Head of the firm’s China Life Sciences Group; with MoFo Partner Chuan Sun, a highly regarded technology transaction lawyer; Partner Rongjing Zhao, an experienced M&A lawyer, and MoFo Partner Lily Li, who frequently advises clients on high-stakes patent litigations. <hr>

ChinaBio® Partnering Forum: Top 5 Risks and Opportunities to Watch in China Life Sciences in 2023

Sign Up

Janet focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet’s clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals.Recognized by Chambers as being highly sought after for patent prosecution and strategy mandates by innovators from around the world, Janet develops and strengthens her clients’ complex patent portfolios to maximize their commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. As impressed clients noted to Chambers, “Janet’s work is thorough, polished and always of the highest caliber. She is well equipped to advise international clients on patent prosecution and strategy in the biotech industry, drawing on substantial technical knowledge.”Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. She helps some of the world’s most-sophisticated biopharmaceutical companies and investors assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is noted for her in-depth knowledge of patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works regularly with patent litigators in the event of legal challenges by third-party competitors or vice versa, and she is frequently called upon to represent clients in litigation and post-grant proceedings.Janet is the Head of firm’s China Life Sciences Group and served as co-chair of the global Life Sciences Group from 2016 to 2019. She is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Chambers Global praises her as an outstanding IP lawyer “who is renowned for her work on IP issues concerning complex cross-border transactions, where she regularly advises Chinese clients.” In a recent edition of Chambers Global, a client says, “Janet . . . is very experienced in advising life sciences clients doing business in China and the US . . . She is highly responsive and always gives practical advice. Her IP expertise adds tremendous value to our business.”Since 2005, Janet has been actively involved in the leadership team of the Chinese-American Biopharmaceutical Society (CABS), a nonprofit organization dedicated to bridging the life sciences communities in the U.S. and China, including serving as president for the 2011–2012 term. She is also a member of BayHelix, a nonprofit organization of Chinese heritage leaders in the global life sciences and healthcare fields.

肖荐（Janet Xiao）博士的业务侧重于为生命科学公司处理在全球范围内的专利采购、专利组合管理和战略策划事宜。肖博士服务的客户范围广泛，包括大型跨国生物制药公司，例如赛尔基因公司（Celgene）和基因泰克公司（Genentech），也包括全球范围的新兴创业公司。她经常就与各种技术有关的专利事宜向客户提供法律意见，其中涉及的技术包括抗体疗法、细胞疗法、纳米医学、基因疗法、给药系统、诊断和和营养学等。来自全球的创新者纷纷向肖博士寻求专利申请和专利战略的法律咨询，这一点也得到了《钱伯斯指南》的认可。她帮助客户开发和加强其复杂的专利组合，从而为客户实现最大的商业价值。在为制药行业的客户制定数十亿美元专利组合的战略方面，肖博士发挥着重要的作用。《钱伯斯指南》曾引用客户评价称，“肖博士是我曾合作过的律师当中知识最渊博、效率最高的一位律师。她能很好地将专利组合的历史信息用于全球专利申请问题上。”肖博士针对风险投资、技术交易、并购和生物医药产品的市场推广与生产许可事宜开展广泛的知识产权尽职调查审查工作。她协助世界上一些最成功的生物制药公司和投资者，为其产品开发和投资评估潜在风险，并制定先发制人的风险管理策略。她曾牵头处理过数百个知识产权尽职调查项目，并凭借自己对癌症免疫治疗、基因编辑、新一代测序、液体活检、抗体制造和医疗设备领域的专利方面的深厚知识而闻名。肖博士时常与专利诉讼律师合作，处理由第三方竞争者提出的法律质疑，或对第三方竞争者提出的法律质疑，她还经常受聘代表客户处理专利诉讼和授予后程序。肖博士是美富中国生命科学业务组主管，她曾在2016至2019期间担任美富全球生命科学业务组的联席主管。肖博士是全球为数不多的既拥有很强的全球战略性知识产权管理技能，同时又对中国和中国客户独特的知识产权问题具有深刻理解的知识产权律师之一，她一直是处理中美跨境交易和在中国境内经营中所涉知识产权问题的首选律师。《钱伯斯全球指南》称赞她是一位优秀的知识产权律师，“她因处理与复杂跨境交易有关的知识产权问题工作而知名，经常代表中国客户处理这方面的事宜” 。在近期一版《钱伯斯全球指南》中，某客户评价称，“肖博士在为于中国和美国开展业务的生命科学客户提供法律意见方面，有非常丰富的经验。她非常负责而且总是提供切实可行的法律意见。她在知识产权方面的专业意见为我们的业务增添了巨大价值。”自2005年以来，肖博士一直积极参与北美华人生物医药协会（CABS）的领导工作。该协会是一家非营利组织，致力于成为连接中美两国生命科学领域的纽带。肖博士在2011至2012年间担任该协会主席。她还是百华协会（BayHelix）的成员。百华协会是一家非营利组织，由全球生命科技和医疗保健产业领域的华人精英组成。

Janet Xiao

Partner

Chuan focuses his practice on cross-border M&A transactions; sophisticated technology, media, and telecom (TMT) transactions; and complex IP/commercial matters across Greater China.With 20 years of experience in both Asia and the U.S., Chuan regularly advises multinational corporations, state-owned enterprises, private companies, and PE/VC firms in complex cross-border M&A transactions, joint ventures, strategic alliances, and business separation transactions.Chuan also has significant experience in strategic corporate-commercial and technology transactions, including outsourcing, manufacturing, distribution, supply and franchising arrangements, and IP licensing arrangements across multiple industries. His TMT and IP regulatory experience includes telecommunications, e-commerce, internet, cyber security, data privacy, cloud computing, as well as telematics.Prior to joining MoFo, he worked in the Hong Kong office of a Magic Circle firm and the Chicago office of another leading international firm.Chuan co-authored the Hong Kong & mainland China chapters of Getting the Deal Through – Telecoms and Media, 2014, 2015 & 2016; the Hong Kong & mainland China chapters of Getting the Deal Through: Market Intelligence – Telecoms and Media, 2015; and the Hong Kong chapter of Sourcing World 2nd Edition 2015.Chuan is fluent in Mandarin and English.“Chuan Sun has a wealth of knowledge on his clients’ existing products and services offerings and a good understanding of what terms they are or are not willing to accept. This helps tremendously with contract negotiations.”“Chuan Sun has extensive experience in the technology space. Many other competitor firms in the technology space are not really pure IT lawyers, as they are more focus on privacy and trade marks or other related fields, as opposed to technology contracts such as SAP or Microsoft software license agreements. A normal general commercial lawyer would not be able to identify the same issues or raise the right questions, as they are not equipped with the technology know-how of the products and services, their benefits, and general industry standard terms and trending patterns in the market.” Legal 500 Asia Pacific 2020

孙川律师的执业领域集中在大中华区的跨境并购交易，复杂的技术、媒体和电信(TMT)交易以及复杂的知识产权/商务事宜。孙律师在亚洲和美国有19年工作经验，他经常代理跨国公司、国有企业、私人企业和私募股权/风险投资机构处理复杂的跨境并购交易、合资、战略联盟和业务拆分等交易。孙律师在战略性的公司商务和技术交易方面也拥有极为丰富的经验，包括外包、制造、分销、供应与特许经营安排，以及跨行业知识产权许可安排等。他在TMT和知识产权监管方面的经验包括电信、电子商务、互联网、网络安全、数据隐私、云计算以及车联网。在加入美富前，孙律师在一家 “魔法圈”律所(Magic Circle)的香港办事处和另一家领先的国际律所的芝加哥办事处工作。孙律师与他人合著了2014，2015和2016版《让交易推进下去––电信与媒体》(Getting the Deal Through – Telecoms and Media)中的香港和中国大陆章节，2015年版《让交易推进下去：市场情报––电信与媒体》(Getting the Deal Through: Market Intelligence – Telecoms and Media)中的香港和中国大陆章节，以及2015年《采购世界》第二版(Sourcing World 2nd Edition)的香港章节。2018年《亚太法律500强》指出“孙川律师十分高效、负责和实际。他非常擅长处理IT协议，包括软件许可和IT采购合同的相关事宜。他也十分善于处理跨境TMT交易。”孙律师精通普通话和英语。

Chuan Sun

Managing Partner, Shanghai

Rongjing has extensive experience advising private equity firms, institutional investors and major corporations on complex cross-border transactions, including control deals and leveraged buyouts, mergers and acquisitions, growth capital investments, spin-offs, and distressed M&A transactions. She primarily represents private equity funds on investments and acquisitions in China and the rest of Asia. She also advises clients on take privates of U.S.-listed companies and other U.S. public and private company M&A transactions. Rongjing works across a range of sectors, with a particular interest and focus in the technology sector. Prior to joining MoFo, Rongjing was a partner in a leading international law firm’s Hong Kong and Shanghai offices for several years. She is a native Mandarin speaker and fluent in English. <h4>Representative Matters</h4><h5>Private Equity Investments and Controlling/Buyout Transactions </h5><ul><li>The Carlyle Group <ul><li>in its leveraged buyout of HCP Packaging, a global designer and manufacturer of packaging containers for the beauty industry, from Baring Private Equity Asia. This transaction was included in “Deals of the Year 2022” by China Business Law Journal;</li><li>in its US$1.05 billion leveraged buyout of VXI Global Solutions, a U.S.-based multinational service provider with major operations in the United States, Southeast Asia, Europe, and China; </li><li>and Anchor Equity Partners in their respective investments in Airoha Technology Corp., a global leading communications solutions fabless integrated circuit design house based in Taiwan, majority-owned and controlled by MediaTek Inc. (TWSE: 2454);  </li><li>with CITIC Limited and CITIC Capital Holdings in the US$2.08 billion acquisition of the McDonald’s operations in China and Hong Kong and negotiation of a 20-year master franchise agreement―the largest McDonald’s franchise in the world; </li><li>in its US$150 million investment in OneSmart Education Group (NASDAQ: ONE); </li><li>in its pre-IPO investment in Neiwai Inc., a Shanghai-based lingerie retail group; and</li><li>in its RMB530 million investment in Beijing Ubox Technology & Trade Co., Ltd, a leading vending machine operator in China. </li></ul></li><li>Centurium Capital in its US$150 million pre-IPO investment in NTX Group, a global textile technology company.</li><li>China International Capital Corporation in its pre-IPO convertible bond investment of an auto finance company and the subsequent restructuring and litigation. </li><li>Clearlake Capital Group and its portfolio company Alkegen, one of the largest specialty materials platforms in the world, on its US$470 million partial tender offer in Luyang Energy-Saving Materials Co. Ltd., a Shenzhen Stock Exchange-listed company (SZSE: 002088). </li><li>Coatue Management in its investment in Niutron Technologies, AI Rudder Technologies, Rox (Cay) Holdings Ltd; and the US$700 million pre-IPO investment in Dingdong Maicai (NYSE: DDL).  </li><li>KKR in its US$645 million sale of MMI Holdings to a Chinese consortium and the subsequent restructuring to regain control. </li></ul><h5>Cross-Border/Public M&A Transactions  </h5><ul><li>Ocumension Therapeutics (HKSE: 1477) in its PIPE investment in Alimera Sciences, Inc., a U.S. pharmaceutical company (NASDAQ: ALIM). </li><li>Sea Limited (NYSE: SE) in its acquisition of Phoenix Labs, an acclaimed independent games development company based in Vancouver.</li><li>Vimicro International Corp (NASDAQ: VIMC) in its going-private transaction.</li><li>Webull Corporation in three rounds of equity financings and pre-IPO financing, which raised over US$460 million in total. </li></ul>

赵蓉婧律师为私募股权基金、机构投资者和大型企业提供建议，对处理复杂的跨境交易（包括控股交易和杠杆收购、并购、成长型资本投资、分拆和困境企业并购交易）拥有丰富经验。赵律师主要代表私募股权基金处理其在中国和亚洲其他地区的投资和收购交易，她还就美国上市公司的私有化和其他美国上市及私有公司涉及的交易为客户提供建议。赵律师的业务涵盖各类行业领域，其中尤其侧重于科技领域。在加入美富之前，赵律师曾在一家领先的国际律师事务所的香港和上海办事处担任合伙人数年。赵律师的母语为普通话，精通英语。<h4>具有代表性的交易</h4><h5>私募股权投资和控股/收购交易 </h5><ul><li>代表凯雷投资集团 <ul><li>处理其向霸菱亚洲投资基金对HCP Packaging公司进行的杠杆收购。HCP Packaging是一家美容行业包装容器的全球设计与制造商，该交易被《商法》杂志评为“2022年度交易”；</li><li>处理其以10.5亿美元对VXI Global Solutions进行的杠杆收购，该公司是一家美国跨国服务提供商，在美国、东南亚、欧洲和中国有大量业务；</li><li>处理其和Anchor Equity Partners分别投资达发科技股份有限公司的事宜。达发科技是一家全球领先的通信解决方案无晶圆厂集成电路设计公司，其总部位于台湾，由联发科技股份有限公司（台交所代码：2454）持有多数股权并控制；</li><li>处理其与中信股份有限公司和中信资本控股组成的联合投资团以20.8亿美元收购麦当劳中国内地和香港业务的事宜，以及关于有效期20年的特许经营主协议的谈判（是麦当劳在全球规模最大的特许经营权）；</li><li>处理其针对精锐教育集团（纳斯达克代码：ONE）的1.5亿美元投资；</li><li>处理其对中国内衣零售集团内外集团的上市前投资；以及</li><li>处理其针对中国领先的售货机经营商北京友宝科斯科贸有限公司的人民币5.3亿元投资。</li></ul></li><li>代表大钲资本处理其针对全球纺织技术公司NTX Group的1.5亿美元上市前投资。</li><li>代表中国国际金融股份有限公司处理其对一家汽车金融公司的上市前可转换债券投资以及此后的重组和诉讼事宜。</li><li>代表清湖资本集团及其投资组合公司奇耐亚太处理其以4.7亿美元对深圳证券交易所上市公司山东鲁阳节能材料股份有限公司（深交所代码：002088）的部分要约收购。奇耐亚太是全球最大的特种材料平台之一。</li><li>代表Coatue Management处理其对Niutron Technologies、AI Rudder Technologies、Rox (Cay) Holdings Ltd的投资，及其对叮咚买菜（纽交所代码：DDL）的7亿美元上市前投资。</li><li>代表KKR公司处理其以6.45亿美元将MMI Holdings公司出售给一个中国财团，以及其后为重获控股权进行的重组事宜。</li></ul><h5>跨国并购/上市公司并购交易 </h5><ul><li>代表欧康维视生物（港交所代码：1477）处理其对美国制药公司Alimera Sciences, Inc.（纳斯达克: ALIM）进行PIPE投资的事宜。</li><li>代表冬海集团（纽交所代码：SE）处理其收购总部位于温哥华的知名独立游戏开发公司Phoenix Labs。</li><li>代表中星微电子有限公司（纳斯达克代码：VIMC）处理其私有化交易。</li><li>代表微步集团 (Webull Corporation)处理其三轮股权融资和上市前融资事宜，共筹集超过4.6亿美元。</li></ul>

Rongjing Zhao

Lily Li is a partner in the firm’s Litigation Group. She has represented companies in high-stakes patent litigation, trade secret matters, competitor cases, non-practicing entity assertions, and commercial disputes.Leveraging her in-house experience and technical expertise, Lily collaborates with clients to create and execute effective legal strategies that achieve their business objectives. Lily has litigated before state and federal courts, the International Trade Commission, international arbitration tribunals, and the U.S. Patent and Trademark Office. Her matters have spanned a wide range of technologies, including computer hardware and software, semiconductors, autonomous driving, aviation, consumer electronics, wireless communication, medical devices, and pharmaceuticals. Lily has been repeatedly recognized as one of the “Ones to Watch” by Best Lawyers, a “Rising Star” by Managing IP, and a “Rising Star” by Super Lawyers.Lily frequently advises domestic and international clients in complex cross-border disputes. She was selected to participate in the Federal Circuit Bar Association’s Global Fellows program in 2023-2024, which brings together emerging leaders from the global IP community.Lily is devoted to promoting justice and committed to pro bono work. She has volunteered countless hours to litigate matters to champion human rights and improve children’s public education.During and before law school, Lily was an intellectual property manager for a semiconductor company, where she prosecuted patent applications and strategized the company’s global patent portfolios. Lily earned her bachelor’s degree in electrical engineering. She also studied and researched artificial intelligence during graduate school and published articles, including in the IEEE Transactions on Neural Networks.Lily is a native Mandarin speaker and is admitted to practice in California and before the U.S. Patent and Trademark Office and Federal Circuit.

ChinaBio® Partnering Forum: Top 5 Risks and Opportunities to Watch in China Life Sciences in 2023

20 Sep 2023 1:30 PM - 2:30 PM HKT